Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

References

• Cavallaro U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression. J Neurooncol 2000; 50:63–70.
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15–8.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–27.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005; 65:671–80.
   PubMed Web of Science ®Google Scholar
• Genentech BioOncology. Avastin (bevacizumab), product insert. Last accessed on June, 2009 [cited; Available from: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
   Google Scholar
• Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Colangelo LH, Lopa SH, . Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27:3385–90.
   PubMed Web of Science ®Google Scholar
• Karrison T, Kindler HL, Gandara DR, Lu C, Guterz TL, Nichols K, . Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). ASCO Meeting Abstracts 2007;25(18 Suppl):7526.
   Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, . A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. ASCO Meeting Abstracts 2007;25(18 Suppl):4508.
   Google Scholar
• Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, . Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830–5.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3):25–33.
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, . Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232–9.
   PubMed Web of Science ®Google Scholar
• Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med 1997;127:531–7.
   PubMed Web of Science ®Google Scholar
• National Cancer institute’s common toxicity criteria (version 2). Last accessed on March, 2009. 1999 [cited; Available from: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
   Google Scholar
• National Cancer institute’s common toxicity criteria (version 3). Last accessed on March, 2009. 2006 [cited; Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf
   Google Scholar
• Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 2009;10:559–68.
   PubMed Web of Science ®Google Scholar
• Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008;300:2277–85.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis 2007;49:186–93.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820–6.
   PubMed Web of Science ®Google Scholar
• Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, . Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;370(9605): 2103–11.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, . Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231–7.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, . Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227–34.
   PubMed Web of Science ®Google Scholar
• Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, . Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. ASCO Meeting Abstracts 2008;26(15 Suppl):LBA1011.
   Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, . Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005;23:3502–8.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, . Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013–9.
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, . Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, . Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–91.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, . A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34.
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, . Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005; 23:3697–705.
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, . Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539–44.
   PubMed Web of Science ®Google Scholar
• Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, . Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26: 5422–8.
   PubMed Web of Science ®Google Scholar
• Price TJ, Gebski V, van Hazel GA, Robinson BA, Broad A, Ganju V, . International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. ASCO Meeting Abstracts 2008;26 (15 Suppl):4029.
   Google Scholar
• Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357: 2666–76.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542–50.
   PubMed Web of Science ®Google Scholar
• Herbst RS, O’Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, . Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007;25:4743–50.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, . Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–9.
   PubMed Web of Science ®Google Scholar
• Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, . Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002;22:1500–5.
   PubMed Web of Science ®Google Scholar
• Hesser BA, Liang XH, Camenisch G, Yang S, Lewin DA, Scheller R, . Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. Blood 2004;104:149–58.
   PubMed Web of Science ®Google Scholar
• Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375–86.
   PubMed Web of Science ®Google Scholar
• Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003;21:3542; author reply 3.
   PubMed Web of Science ®Google Scholar
• Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, . Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992;86: 1302–9.
   PubMed Web of Science ®Google Scholar
• de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85: 2284–90.
   PubMed Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, Langer F, Desai H, Davila M, . Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7:171–81.
   PubMed Web of Science ®Google Scholar
• Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: A double edged sword? Eur Heart J 2008;29:2325–6.
   PubMed Web of Science ®Google Scholar
• Bando H, Brokelmann M, Toi M, Alitalo K, Sleeman JP, Sipos B, . Immunodetection and quantification of vascular endothelial growth factor receptor-3 in human malignant tumor tissues. Int J Cancer 2004;111:184–91.
   PubMed Web of Science ®Google Scholar
• Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, . Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51: 168–73; Discussion 74.
   PubMed Web of Science ®Google Scholar
• Weich HA, Bando H, Brokelmann M, Baumann P, Toi M, Barleon B, . Quantification of vascular endothelial growth factor-C (VEGF-C) by a novel ELISA. J Immunol Methods 2004;285:145–55.
   PubMed Web of Science ®Google Scholar
• Alkindi S, Dennison D, Pathare A. Arterial and venous thrombotic complications with thalidomide in multiple myeloma. Arch Med Res 2008;39:257–8.
   PubMed Web of Science ®Google Scholar
• Scarpace SL, Hahn T, Roy H, Brown K, Paplham P, Chanan-Khan A, . Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma 2005;46:239–42.
   PubMed Web of Science ®Google Scholar
• Altintas A, Ayyildiz O, Atay AE, Cil T, Isikdogan A, Muftuoglu E. Thalidomide-associated arterial thrombosis: Two case reports. Ann Acad Med Singapore 2007; 36: 304–6.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, . Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125–34.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, . Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204–12.
   PubMed Web of Science ®Google Scholar